GLP‐1 RA use was associated with a greater reduction in risk (14%), driven specifically by a lower risk of hepatocellular, colorectal, gallbladder, gastric, pancreas, oesophageal, brain, oral cavity, and head and neck cancers. This evidence concerns the gene GLP1R and head and neck cancer.